ArticleiLIVER2026
The impact of blood ammonia after interventional therapy on the prognosis of patients with unresectable hepatocellular carcinoma.
Article in iLIVER, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a dismal prognosis. Interventional therapy serves as a main therapeutic approach for unresectable HCC. This study aimed to investigate the impact of post-interventional blood ammonia (BLA) levels on the prognosis of patients with unresectable HCC, to provide a reference for clinical risk stratification and individualized treatment. Methods: A retrospective study was conducted, enrolling patients with unresectable HCC admitted to Senior Department of Hepatology, Chinese PLA General Hospital from August 2022 to September 2025. According to the BLA levels within 1 week after interventional therapy, the patients were divided into the BLA < 50 μmol/L group and the BLA ≥ 50 μmol/L group. The clinical characteristics, interventional treatment modalities (hepatic arterial infusion chemotherapy [HAIC] or transcatheter arterial chemoembolization [TACE]), and laboratory indicators of the patients were collected. The Kaplan-Meier method was used for survival analysis, and the Cox proportional hazards regression model was applied to analyze the prognostic factors. Results: A total of 209 patients were enrolled in this study, including 178 males (85.2%); the mean age was 56.6 ± 9.5 years. By the last follow-up, 110 patients were still alive, and 99 had died. The objective response rate (ORR) and disease control rate (DCR) in the BLA ≥ 50 μmol/L group were significantly lower than those in the BLA < 50 μmol/L group after interventional therapy (ORR: 12.2% vs. 24.4%, Conclusion: Elevated BLA (≥ 50 μmol/L) after interventional therapy is an independent risk factor for poor prognosis in patients with unresectable HCC, and HAIC treatment may improve the survival of such patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.